Pharmacogenomics-Guided Therapy for Complex Diseases: Applications in Cardiovascular Disease, Breast Cancer, and Mental Health

Abstract

Pharmacogenomics-based therapy is a revolutionary perspective of precision medicine, as it allows clinicians to personalize drug therapy based on patient genetic characteristics. The paper assessed the clinical and economic outcomes of the application of genotype-based therapy in three conditions of complex diseases, including cardiovascular disease, breast cancer, and mental health disorders, based on primary patient data in tertiary hospitals in Pakistan. Four hundred and fifty patients were recruited and put into a pharmacogenomics-guided (PGx) cohort or a standard therapy cohort. The influence of genetic variations on the drug metabolite and response to the treatment was studied on CYP2C19, SLCO1B1, VKORC1, CYP2D6, UGT1A1, and SLC6A4. The group directed by the PGx showed much more therapeutic efficacy, lower adverse drug reactions, and better cost-effectiveness in comparison with conventional care ( p. 0.05). Regression analysis was used to confirm that certain variations CYP2C19 and CYP2D6 among others were good predictors of clinical outcomes. These developments underscore the utility of pharmacogenomics in the improvement of drug safety and efficacy, minimization of the healthcare costs and sealing the outlook of the gap between genomic science and clinical practice. The paper highlights the need to ensure the incorporation of pharmacogenomic testing into the healthcare systems particularly in developing nations as a way of encouraging evidence-based and customized therapeutics of complicated diseases.